Humacyte Inc. (NASDAQ: HUMA) announced the pricing of an underwritten public offering of 47.6 million shares of common stock at $1.05 per share, with expected gross proceeds of approximately $50 million before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 7.1 million shares at the public offering price. The offering is expected to close on or about June 12, 2026, subject to customary closing conditions.
Humacyte said it intends to use the net proceeds to support commercialization of Symvess, advance a planned Biologics License Application supplement filing for a hemodialysis indication, fund development of pipeline candidates and provide working capital for general corporate purposes. Barclays, BTIG and Titan Partners, a division of American Capital Partners, are serving as joint book-running managers for the offering.
The company, a commercial-stage biotechnology platform company, develops universally implantable, bioengineered human tissues at commercial scale. In the first quarter of 2025, it commenced the United States commercial launch of Symvess, its first FDA-approved product. Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine.
Humacyte is leveraging its novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. For uses other than the U.S. Food and Drug Administration approval in the extremity vascular trauma indication, the acellular tissue engineered vessel is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
This capital raise underscores the company's need for funding as it scales up Symvess sales and prepares for potential label expansion. The hemodialysis indication represents a significant market opportunity, as vascular access for dialysis is a major unmet need. The offering also provides resources to advance earlier-stage pipeline candidates, including those for other vascular and tissue repair applications.
Investors should note that the offering dilutes existing shareholders, but the proceeds are critical for executing Humacyte's commercial and regulatory strategy. The $50 million gross proceeds, before expenses, will be a key driver of the company's near-term activities, including manufacturing scale-up and clinical trial support for the BLA supplement.
For further information, visit the company's website at https://humacyte.com/. To view the full press release, visit https://ibn.fm/k6T1b.